Insilico expands Tenacia CNS pact in $94.75 million AI deal
CURRENT FULL VERSION: Insilico Medicine is widening its bet on AI-designed neuroscience drugs. On March 26, 2026, the company and Tenacia Biotechnology announced an expansion of their CNS collaboration, adding a second program that aims to discover and advance an additional small-molecule candidate for challenging neurological diseases, with potential deal value of up to $94.75 million in near-term and milestone payments to Insilico. (prnewswire.com)
The move builds on an initial collaboration launched in March 2025. According to the companies, that first phase paired Insilico’s generative AI drug discovery platform, Pharma.AI, with Tenacia’s neuroscience expertise and proprietary data, focusing on small-molecule inhibitors with strong blood-brain barrier permeability for CNS treatment. The partners said progress in that first effort helped justify a broader agreement. (prnewswire.com)
Under the expanded deal, the companies plan to use generative AI to develop another candidate with defined properties and move it to the preclinical candidate stage. Insilico said the goal is to explore molecules with differentiated profiles for nerve system-related conditions, with the idea that better-tuned molecular properties could improve clinical utility and reduce late-stage development risk. That blood-brain barrier emphasis is notable because CNS drug development has long been constrained by delivery challenges as well as high attrition. (prnewswire.com)
The announcement also fits a larger run of business development by both companies. Tenacia, founded in 2022 and backed by Bain Capital, has been building a China-focused neuroscience portfolio through licensing and collaboration deals, including recent and prior agreements involving neurological and neuropsychiatric assets. Insilico, meanwhile, has been using the market to reinforce its position as an AI platform partner: beyond the Tenacia expansion, it also signed a separate multi-program collaboration with Eli Lilly to use Pharma.AI across multiple therapeutic areas. Under that Lilly agreement, Lilly received exclusive global rights to develop, manufacture, and commercialize Insilico’s preclinical oral candidates for selected indications, and the companies agreed to work on multiple R&D programs focused on targets selected by Lilly using Pharma.AI. Insilico is set to receive $115 million upfront under that deal, with total potential value up to $2.75 billion in development, regulatory, and commercial milestones, plus tiered royalties on future sales. (gahbioventures.com)
Company executives framed the Tenacia expansion as evidence that AI can support multi-program work against the same target profile in a compressed timeframe. Insilico founder Alex Zhavoronkov said launching a second program with differentiated attributes “within such a short timeframe” shows the flexibility of generative AI in drug design, while Tenacia said the first year of work demonstrated the value of combining the companies’ respective capabilities. Those are company statements, not independent validation, but they align with Insilico’s broader pitch that AI can compress early discovery: the company has said that from 2021 to 2024 it nominated 20 preclinical candidates in an average of 12 to 18 months per program, compared with traditional timelines measured in years. (prnewswire.com)
Why it matters: For veterinary professionals, this is less about an immediate animal health product and more about where drug discovery infrastructure is heading. Neurology, pain, and other CNS-adjacent conditions remain difficult therapeutic areas in both human and veterinary medicine, in part because brain exposure and target selectivity are so hard to optimize. If AI platforms can reliably improve hit generation and property balancing earlier in discovery, that could eventually lower barriers for animal health companies pursuing neurologic or behavior-related therapeutics, especially in indications where conventional discovery has been slow or expensive. Insilico has explicitly said its platform business extends into veterinary medicine, so the company’s success in human CNS partnerships could have spillover relevance for future animal health collaborations. The Lilly deal adds another layer to that signal because it shows a large pharma company was willing to pay meaningful upfront cash for broad access to the platform, selected preclinical oral assets, and multiple AI-enabled discovery programs rather than a single narrow project. (prnewswire.com)
There’s also a business signal here. Investors and partners continue to reward platform companies that can show repeatable deal flow, milestone-based structures, and evidence that AI tools are useful beyond a single asset. For veterinary industry watchers, that may be the more important takeaway: not that this Tenacia deal changes clinical practice, but that it adds to the growing body of commercial validation around AI-enabled discovery models that may eventually shape companion animal and livestock R&D strategies. That inference is based on Insilico’s expanding cross-sector platform positioning and its recent sequence of partnerships, including the Lilly agreement’s combination of upfront payment, exclusive global rights, milestones, and royalties. (prnewswire.com)
What to watch: The next milestones are whether the added Tenacia program reaches preclinical candidate nomination, whether the companies disclose the target or indication, and whether Insilico’s recent CNS and large-pharma deals translate into more explicit animal health or veterinary drug discovery partnerships over the next 12 to 24 months. The structure of the Lilly collaboration may also serve as a useful marker for how future AI-drug-discovery partnerships are priced and split between platform access, asset rights, milestones, and royalties. (prnewswire.com)